[1] Deng F, Ranta VP, Kidron H, et al. General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms. Pharmaceutical Research, 2016; 33, 2680−90. doi:  10.1007/s11095-016-1993-2
[2] Chow SC, Liu Jp. Design and analysis of bioavailability and bioequivalence studies. Boca Raton: CRC Press, 2009.
[3] Jaki T, Pallmann P, Wolfsegger MJ. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs. Stat Med, 2013; 32, 5469−83. doi:  10.1002/sim.5886
[4] Shen M, Machado SG. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method. J Biopharm Stat, 2017; 27, 257−64. doi:  10.1080/10543406.2016.1265543
[5] Locke CS. An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm, 1984; 12, 649−55. doi:  10.1007/BF01059558
[6] Fieller EC. Some Problems in Interval Estimation. Journal of the Royal Statistical Society. Series B (Methodological), 1954; 14, 175−85.
[7] Jaki T, Wolfsegger MJ, Lawo J-P. Establishing Bioequivalence in Complete and Incomplete Data Designs Using AUCs. J Biopharmaceutical Stat, 2010; 20, 803−20. doi:  10.1080/10543401003618835
[8] Chiambaretta F, Garraffo R, Elena PP, et al. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. Eur J Ophthalmol, 2008; 18, 13−20. doi:  10.1177/112067210801800103
[9] Yan Z. Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs'. Stat Med, 2013; 32, 5484−6. doi:  10.1002/sim.5995
[10] Jones B, Kenward MG. Design and analysis of cross-over trials. Boca Raton: CRC Press/Taylor & Francis, 2014.